NASDAQ: GLMDGalmed Pharmaceuticals Ltd Stock
$1.30-0.07 (-5.11%)
Updated Apr 30, 2025
GLMD Price
$1.30
Fair Value Price
N/A
Market Cap
$2.15M
52 Week Low
$1.21
52 Week High
$23.80
P/E
-0.16x
P/B
0.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$6M
Beta
0.77
Next Earnings
May 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GLMD Overview
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLMD's potential to beat the market
- GLMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLMD
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important GLMD news, forecast changes, insider trades & much more!
GLMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GLMD is good value based on its book value relative to its share price (0.13x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
GLMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GLMD due diligence checks available for Premium users.
Valuation
GLMD fair value
Fair Value of GLMD stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$5.41
Undervalued by
75.95%
GLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
-162.28x
Market
29.18x
GLMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.13x
Industry
4.45x
GLMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
GLMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.5M
Liabilities
$2.2M
Debt to equity
0.13
GLMD's short-term assets ($16.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLMD's short-term assets ($16.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$3.5M
Financing
$448.0k
GLMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLMD vs Biotech Stocks
Galmed Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.